Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRVO CervoMed Inc
- Stocks
- Healthcare
- NASDAQ: CRVO
Price (delayed)
$5.65
Market cap
$49.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.18
Enterprise value
$38.67M
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing
Highlights
CervoMed's EPS has increased by 37% YoY but it has decreased by 8% QoQ
CervoMed's gross profit has increased by 15% YoY but it has decreased by 4.4% from the previous quarter
CRVO's net income is down by 15% QoQ
The company's equity fell by 12% QoQ
Key stats
What are the main financial stats of CRVO
Market
Valuations
Earnings
Shares outstanding
8.7M
Market cap
$49.17M
Enterprise value
$38.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
5.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.15
Revenue
$9.31M
Gross profit
$9.31M
Operating income
-$20.94M
Net income
-$18.67M
EBIT
-$18.67M
EBITDA
-$18.67M
Free cash flow
-$19M
Per share
Balance sheet
Liquidity
EPS
-$2.18
EPS diluted
-$2.18
Free cash flow per share
-$2.18
Book value per share
$3.98
Revenue per share
$1.07
TBVPS
$4.43
Total assets
$38.58M
Total liabilities
$3.94M
Debt
$0
Equity
$34.63M
Working capital
$34.63M
Debt to equity
0
Current ratio
9.78
Quick ratio
9.35
Net debt/EBITDA
0.56
Margins
Efficiency
Dividend
EBITDA margin
-200.6%
Gross margin
100%
Net margin
-200.6%
Operating margin
-224.9%
Return on assets
-40.6%
Return on equity
-44.1%
Return on invested capital
-56.5%
Return on capital employed
-53.9%
Return on sales
-200.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVO stock price
How has the CervoMed stock price performed over time
Intraday
1.62%
1 week
-20.48%
1 month
-25.56%
1 year
-64.4%
YTD
141.45%
QTD
-10.1%
Financial performance
How have CervoMed's revenue and profit performed over time
Revenue
$9.31M
Gross profit
$9.31M
Operating income
-$20.94M
Net income
-$18.67M
Gross margin
100%
Net margin
-200.6%
CRVO's operating income has dropped by 133% year-on-year and by 15% since the previous quarter
The operating margin has plunged by 102% YoY and by 20% from the previous quarter
The net margin has contracted by 20% from the previous quarter
CervoMed's gross profit has increased by 15% YoY but it has decreased by 4.4% from the previous quarter
Price vs fundamentals
How does CRVO's price correlate with its fundamentals
Growth
What is CervoMed's growth rate over time
Valuation
What is CervoMed stock price valuation
P/E
N/A
P/B
1.42
P/S
5.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.15
CervoMed's EPS has increased by 37% YoY but it has decreased by 8% QoQ
The P/B is 53% below the 5-year quarterly average of 3.0 and 32% below the last 4 quarters average of 2.1
The company's equity fell by 12% QoQ
The stock's price to sales (P/S) is 45% less than its last 4 quarters average of 9.6
The revenue rose by 15% YoY but it fell by 4.4% QoQ
Efficiency
How efficient is CervoMed business performance
CervoMed's return on sales has decreased by 20% QoQ
The ROA has contracted by 12% YoY but it has grown by 4.5% from the previous quarter
The company's return on invested capital rose by 7% QoQ
The return on equity has increased by 5% since the previous quarter and by 3.1% year-on-year
Dividends
What is CRVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVO.
Financial health
How did CervoMed financials performed over time
The total liabilities has grown by 48% YoY
The current ratio has contracted by 12% from the previous quarter
The debt is 100% less than the equity
The company's equity fell by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.